Detalhe da pesquisa
1.
Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
J Am Pharm Assoc (2003)
; 62(2): 588-597.e2, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34674965
2.
North Carolina community pharmacists' buprenorphine dispensing practices and attitudes.
J Am Pharm Assoc (2003)
; 62(5): 1606-1614, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35643625
3.
Project ECHO® in Primary Care: Informing Providers about COVID-19 and Its Impact on Health Care Delivery.
N C Med J
; 83(2): 130-133, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35256476
4.
Reprint of: Impact of elective on students' perceptions of treating patients with a substance use disorder.
J Am Pharm Assoc (2003)
; 60(5S): S84-S87, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32977932
5.
Impact of elective on students' perceptions of treating patients with a substance use disorder.
J Am Pharm Assoc (2003)
; 60(4): e43-e46, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107156
6.
Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
J Am Pharm Assoc (2003)
; 59(6): 867-871, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31466899
7.
Physician perceptions of integrating advanced practice pharmacists into practice.
J Am Pharm Assoc (2003)
; 58(1): 73-78.e2, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29175005
8.
Development of a targeted naloxone coprescribing program in a primary care practice.
J Am Pharm Assoc (2003)
; 57(2S): S130-S134, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28189537
9.
The Integral Role of the Clinical Pharmacist Practitioner in Primary Care.
N C Med J
; 78(3): 181-185, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576956
10.
Interprofessional care for patients with osteoporosis in a continuing care retirement community.
J Am Pharm Assoc (2003)
; 56(2): 184-8, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27000170
11.
Evaluation of a Team-Based, Transition-of-Care Management Service on 30-Day Readmission Rates.
N C Med J
; 77(2): 87-92, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26961826
12.
Assessing pharmacist-led annual wellness visits: Interventions made and patient and physician satisfaction.
J Am Pharm Assoc (2003)
; 55(4): 449-54, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26161489
13.
Long-acting, Injectable Buprenorphine: Great Promise, but Significant Barriers to Use.
N C Med J
; 81(3): 210-211, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32366637
14.
Financial implications of pharmacist-led Medicare annual wellness visits.
J Am Pharm Assoc (2003)
; 54(4): 435-40, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25063264
15.
Factors in rural community buprenorphine dispensing.
Explor Res Clin Soc Pharm
; 9: 100204, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36703716
16.
Providing Office-Based Treatment of Opioid Use Disorder.
Ann Fam Med
; 15(5): 481, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28893820
17.
Billing for pharmacists' cognitive services in physicians' offices: multiple methods of reimbursement.
J Am Pharm Assoc (2003)
; 52(2): 175-80, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22370380
18.
An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
J Rural Health
; 37(3): 467-472, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33720447
19.
Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?
J Fam Pract
; 69(10): E14-E15, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33348352
20.
A Financial Model for Team-Based Opioid Use Disorder Treatment.
J Am Board Fam Med
; 33(1): 124-128, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31907253